西黄胶囊联合醋酸甲羟孕酮对子宫内膜癌化疗患者预后及相关指标的影响

doi:10.3969/j.issn.1006-6233.2025.04.028

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1469 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析西黄胶囊联合醋酸甲羟孕酮对子宫内膜癌化疗患者血清微小核糖核酸(miR)-146a、miR-155水平及预后的影响。方法: 选取2019年1月至2022年5月子宫内膜癌化疗患者132例,按随机数字表法分为两组,每组66例。对照组采取醋酸甲羟孕酮治疗,观察组采取西黄胶囊联合醋酸甲羟孕酮治疗,疗程3个月。比较两组疗效、生存率,治疗前、治疗3个月后采用酶联免疫吸附法测定血清肿瘤标志物[人附睾蛋白4(HE4)、糖类抗原125(CA125)、癌胚抗原(CEA)、细胞角蛋白-19片段(CYFRA21-1)]水平,DxFLEX流式细胞仪检测免疫指标CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺,PCR法测定癌基因表达量[原癌基因c-myc、c-erbB2,抑癌基因P16、P53],荧光定量PCR测定miR-146a、miR-155水平变化。结果: 观察组总有效率与对照组比较(65.15%vs42.42%,χ²=6.858,P=0.009);观察组治疗后血清HE4、CA125、CEA、CYFRA21-1水平低于对照组(P<0.05);观察组治疗后CD4⁺、CD3⁺、CD4⁺/CD8⁺、血清miR-146a高于对照组,CD8⁺、miR-155低于对照组(P<0.05);观察组治疗后c-myc、c-erbB2表达量低于对照组,P16、P53表达量高于对照组(P<0.05);观察组治疗后1年、2年生存率98.41%、87.30%高于对照组83.61%、63.93%(P<0.05)。结论: 西黄胶囊联合醋酸甲羟孕酮在降低子宫内膜癌化疗患者肿瘤标志物、增强机体免疫、调控癌基因表达、改善生存预后方面均有良好效果,具有一定临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张丽
	李苗苗
	刘丽则

关键词 ：子宫内膜癌, 西黄胶囊, 醋酸甲羟孕酮, 预后, 疗效

Abstract：Objective: To analyze the effects of Xihuang capsules combined with medroxyprogesterone acetate on serum microRNA (miR)-146a, miR-155 levels, and prognosis in patients with endometrial cancer undergoing chemotherapy. Methods: A total of 132 patients with endometrial cancer undergoing chemotherapy from January 2019 to May 2022 were selected and randomly divided into two groups (n=66 per group). The control group received medroxyprogesterone acetate, while the observation group received Xihuang capsules combined with medroxyprogesterone acetate for 3 months. The efficacy and survival rates of the two groups were compared. Serum levels of tumor markers [human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), and cytokeratin-19 fragment (CYFRA21-1)] were measured using enzyme-linked immunosorbent assay before and after 3 months of treatment. Immune indicators (CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺) were detected using DxFLEX flow cytometry. The expression levels of oncogenes (c-myc, c-erbB2) and tumor suppressor genes (P16, P53) were determined using PCR. The levels of miR-146a and miR-155 were measured using fluorescence quantitative PCR. Results: The total effective rate in the observation group was significantly higher than that in the control group (65.15% vs 42.42%, χ²=6.858, P=0.009). After treatment, the observation group showed lower levels of HE4, CA125, CEA, and CYFRA21-1 compared to the control group (P<0.05). The observation group also exhibited higher levels of CD4⁺, CD3⁺, CD4⁺/CD8⁺, and miR-146a, and lower levels of CD8⁺ and miR-155 compared to the control group (P<0.05). The expression of c-myc and c-erbB2 was lower, while the expression of P16 and P53 was higher in the observation group compared to the control group (P<0.05). The 1-year and 2-year survival rates in the observation group were 98.41% and 87.30%, respectively, significantly higher than those in the control group (83.61% and 63.93%, respectively) (P<0.05). Conclusion: Xihuang capsules combined with medroxyprogesterone acetate effectively reduce tumor markers, enhance immune function, regulate oncogene expression, and improve survival prognosis in patients with endometrial cancer undergoing chemotherapy, demonstrating significant clinical application value.

Key words： Endometrial cancer Xihuang capsule Medroxyprogesterone acetate Prognosis Therapeutic effect

基金资助:山西省科学技术研究与开发项目,(编号:201901D1292030)

引用本文:

张丽, 李苗苗, 刘丽则. 西黄胶囊联合醋酸甲羟孕酮对子宫内膜癌化疗患者预后及相关指标的影响[J]. 河北医学, 2025, 31(4): 691-696.
ZHANG Li, LI Miaomiao, LIU Lize. Effect of Xihuang Capsules Combined with Medroxyprogesterone Acetate on the Prognosis and Related Indicators of Endometrial Cancer Patients Undergoing Chemotherapy. HeBei Med, 2025, 31(4): 691-696.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.04.028 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I4/691

[1] Crosbie EJ,Kitson SJ,McAlpine JN,et al.Endometrial cancer[J].Lancet,2022,399(10333):1412-1428.
[2] Zurcher A,Knabben L,von Gernler M,et al.Depot medroxyprogesterone acetate and breast cancer:a systematic review[J].Arch Gynecol Obstet,2024,309(4):1175-1181.
[3] Cai Yx,Wang B,Xu W,et al.Endometrial cancer:genetic,metabolic characteristics,therapeutic strategies and nanomedicine[J].Curr Med Chem,2021,28(42):8755-8781.
[4] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):501-512.
[5] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[6] Yen TT,Wang TL,Fader AN,et al.Molecular classification and emerging targeted therapy in endometrial cancer[J].Int Gynecol Pathol,2020,39(1):26-35.
[7] 徐凌燕,王丹.醋酸甲羟孕酮联合化疗对子宫内膜癌术后患者的治疗效果[J].癌症进展,2023,21(23):2572-2574,2633.
[8] 王璟,卢有媛,谢明霞,等.基于文献计量分析牛黄类药材及其中成药的研究现状[J].中国中药杂志,2023,48(8):2092-2102.
[9] Liu CS,Chen ZL,Wu SLY,et al.Comparative review of effects of pien tze huang and angong niuhuang pill and their potential on treatment of central nervous system diseases[J].Mini Rev Med Chem,2022,22(18):2350-2360.
[10] 汪爱华,张飞忠,王红英.麝香酮调节SHH介导的自噬对卵巢癌细胞恶性进展的影响[J].天津医药,2024,52(2):142-148.
[11] Batiha GE,Wasef L,Teibo JO,et al.Commiphora myrrh:a phytochemical and pharmacological update[J].Naunyn Schmiedebergs Arch Pharmacol,2023,396(3):405-420.
[12] Vermij L,Smit V,Nout R,et al.Incorporation of molecular characteristics into endometrial cancer management[J].Histopathology,2020,76(1):52-63.
[13] Jamieson A,Vermij L,Kramer CJH,et al.Clinical behavior and molecular landscape of stage I p53-abnormal low-grade endometrioid endometrial carcinomas[J].Clin Cancer Res,2023,1(23):4949-4957.
[14] Drissennek L,Baron C,Brouillet S,et al.Endometrial miRNome profile according to the receptivity status and implantation failure[J].Hum Fertil (Camb),2022,25(2):356-368.